RECALL: Bedford Labs Recalls Leucovorin Calcium Injection

Share this article:

Bedford Laboratories announced a nationwide voluntary recall for three lots of leucovorin calcium injection. 

The recall affects the following products:

  • Leucovorin calcium injection, 500mg SDV – Lot# 2017620; Exp. Date 1/31/2013 and Lot #2038374; Exp. Date 2/28/2013
  • Leucovorin calcium injection, 500mg SDV NOVA PLUS – Lot# 2038374A; Exp. Date 2/28/2013

The recall is being conducted due to the discovery of visible crystalline particulate matter in a small number of vials. The particulate matter has been identified as active drug substance and as a potential health hazard. Adverse reactions may include vein irritation and phlebitis, clinically occult pulmonary granulomas detected at routine autopsy examination, local tissue infarction, severe pulmonary dysfunction, occlusion of capillaries and arteries, anaphylactic shock and death.

Leucovorin calcium, a folic acid derivative, is indicated in rescue treatment after high-dose methotrexate therapy in osteosarcoma, megalobastic anemia due to folic acid deficiency when oral therapy is not feasible, and palliative treatment of advanced colorectal cancer in combination with 5-fluorouracil.

For more information call (800) 521-5169 or visit www.bedfordlabs.com.

Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Safety Alerts and Recalls

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs